Procter & Gamble Health
NSE: PGHL · ISIN INE199A01012 · Healthcare
₹5,673.50−43.00 (−0.75%)
Monday 9 November, 12:57 IST. Delayed. Source: Yahoo Finance.
Price chart
₹5,673.50 −43.00 (−0.75%) today
The day
- Previous close
- ₹5,716.50
- Open
- ₹5,716.50
- Day high
- ₹5,760.00
- Day low
- ₹5,632.50
Listed on NSE since 24 April 1996.
Key numbers
- Market value
- ₹9,489.04 Cr
- P/E (trailing)
- 27.26
- EPS (trailing)
- ₹209.67
- Price to book
- 14.42
- Dividend yield
- 2.79%
- Return on equity
- 59.5%
- Debt to equity
- 0.01
- Profit margin
- 25.5%
- Beta
- 0.16
- Volume today
- 2,966
- Average volume
- 12,703
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| Year to June 2022 | ₹1,092.04 Cr | ₹192.52 Cr |
| Year to June 2023 | ₹1,205.86 Cr | ₹229.47 Cr |
| Year to June 2024 | ₹1,129.49 Cr | ₹200.98 Cr |
| FY26 | ₹1,385.12 Cr | ₹326.91 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹382 Cr | ₹112 Cr | +25.9% |
| Q1 FY27Apr–Jun 2026 | ₹364 Cr | ₹96 Cr | +45.3% |
| Q4 FY26Jan–Mar 2026Audited | ₹370 Cr | ₹95 Cr | +54.6% |
| Q3 FY26Oct–Dec 2025 | ₹374 Cr | ₹78 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹325 Cr | ₹89 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹339 Cr | ₹66 Cr | – |
Source: Procter & Gamble Health’s results filed with NSE, standalone (the company alone). Net profit is the share of Procter & Gamble Health’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹103 Cr | ₹113 Cr |
| Inventories | ₹137 Cr | ₹137 Cr |
| Owed by customers | ₹176 Cr | ₹164 Cr |
| Cash and equivalents | ₹323 Cr | ₹177 Cr |
| Total assets | ₹1,015 Cr | ₹841 Cr |
| Borrowings | ₹0 | ₹0 |
| Total liabilities | ₹357 Cr | ₹317 Cr |
| Shareholders’ equity | ₹658 Cr | ₹525 Cr |
Source: Procter & Gamble Health’s half-yearly statements of assets and liabilities filed with NSE, standalone. Companies file these every September and March.
About Procter & Gamble Health
Procter & Gamble Health Limited manufactures and markets pharmaceutical and chemical products in India and internationally. It offers over-the-counter products, vitamins, minerals, and supplements under the Betamil, Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen brand names. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. The company operates as a subsidiary of Procter & Gamble Overseas India B.V.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Mumbai
- Employees
- 1,276
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Procter & Gamble Health in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 45 Per Share
Dividend · ex-date 27 August 2026
- Interim Dividend - Rs 110 Per Share & Special Dividend Rs 50 Per Share
Dividend · ex-date 12 February 2026
- Dividend - Rs 45 Per Share
Dividend · ex-date 22 August 2025
- Interim Dividend - Rs 80 Per Share
Dividend · ex-date 21 February 2025
- Annual General Meeting/Dividend - Rs 60 Per Share
Dividend · ex-date 28 November 2024
- Interim Dividend - Rs 50 Per Share & Special Dividend Rs 150 Per Share
Dividend · ex-date 14 February 2024
- Annual General Meeting/Dividend - Rs 50 Per Share
Dividend · ex-date 23 November 2023
- Interim Dividend - Rs 45 Per Share
Dividend · ex-date 13 February 2023
Source: NSE. Latest first, 8 of 20.
Information only, not investment advice. Prices are delayed.